Option Care Health (NASDAQ:OPCH) just sent its stock soaring 10% after dropping some big news this morning. The company, America's top player in home infusion services, expects Q4 2024 revenue to hit $1.34$1.35 billiona massive 20% jump compared to last year. Adjusted EBITDA is projected to climb up to $121.7 million, while full-year 2024 revenue is set to crack $5 billion. And for 2025? The company is aiming even higher, despite some bumps from Stelara pricing adjustments.
But here's what's really firing up Wall Street: a brand-new $500 million stock buyback program. After wrapping up a $90 million repurchase late last year, Option Care Health's board decided to up the antebig time. This move signals the company's confidence in its future, backed by solid cash flow of $300 million in 2024 and a healthy $412.6 million cash cushion. Share repurchases will roll out strategically, depending on market vibes and corporate priorities.
The market loves a good growth story paired with shareholder rewards, and Option Care Health is delivering both in spades. With momentum on its side, cash in the bank, and a bold repurchase strategy, the company is staking its claim as a standout in the healthcare spaceand investors are piling in for the ride.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.